| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
|
Makielski, Rory J.
|
|
2015
|
76 |
2 |
p. 317-323
|
artikel
|
| 2 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma
|
Kim, Mi Na
|
|
2015
|
76 |
2 |
p. 257-267
|
artikel
|
| 3 |
Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist
|
Ezaki, Taisuke
|
|
2015
|
76 |
2 |
p. 301-306
|
artikel
|
| 4 |
Elemental diet moderates 5-fluorouracil-induced gastrointestinal mucositis through mucus barrier alteration
|
Kawashima, Rei
|
|
2015
|
76 |
2 |
p. 269-277
|
artikel
|
| 5 |
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse
|
Yamashita, Fumiaki
|
|
2015
|
76 |
2 |
p. 325-333
|
artikel
|
| 6 |
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703
|
Kudo, Kenichiro
|
|
2015
|
76 |
2 |
p. 251-256
|
artikel
|
| 7 |
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis
|
Nomura, Motoo
|
|
2015
|
76 |
2 |
p. 357-363
|
artikel
|
| 8 |
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4–p53 interaction
|
Christner, Susan M.
|
|
2015
|
76 |
2 |
p. 287-299
|
artikel
|
| 9 |
Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?
|
Porcelli, Letizia
|
|
2015
|
76 |
2 |
p. 433-438
|
artikel
|
| 10 |
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
|
Wu, Hongyan
|
|
2015
|
76 |
2 |
p. 307-315
|
artikel
|
| 11 |
Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
|
Farhat, Fadi S.
|
|
2015
|
76 |
2 |
p. 235-242
|
artikel
|
| 12 |
Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies
|
Wu, Benjamin
|
|
2015
|
76 |
2 |
p. 243-250
|
artikel
|
| 13 |
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
|
Chua, Clarinda
|
|
2015
|
76 |
2 |
p. 397-408
|
artikel
|
| 14 |
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
|
Matulonis, Ursula
|
|
2015
|
76 |
2 |
p. 417-423
|
artikel
|
| 15 |
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma
|
Chastagner, Pascal
|
|
2015
|
76 |
2 |
p. 425-432
|
artikel
|
| 16 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer
|
Ueda, Shinya
|
|
2015
|
76 |
2 |
p. 279-285
|
artikel
|
| 17 |
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
|
Doi, Toshihiko
|
|
2015
|
76 |
2 |
p. 409-416
|
artikel
|
| 18 |
Population pharmacokinetics of kahalalide F in advanced cancer patients
|
Miguel-Lillo, Bernardo
|
|
2015
|
76 |
2 |
p. 365-374
|
artikel
|
| 19 |
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives
|
Minguet, Joan
|
|
2015
|
76 |
2 |
p. 219-233
|
artikel
|
| 20 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells
|
Kraus, Johannes
|
|
2015
|
76 |
2 |
p. 383-396
|
artikel
|
| 21 |
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy
|
Mitsui, Yasuhiro
|
|
2015
|
76 |
2 |
p. 375-382
|
artikel
|
| 22 |
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363
|
Yates, James W. T.
|
|
2015
|
76 |
2 |
p. 343-356
|
artikel
|
| 23 |
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study
|
Nagao, Shoji
|
|
2015
|
76 |
2 |
p. 335-342
|
artikel
|
Tijdschrift beschrijving